Pitcairn’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $889K | Buy |
8,513
+4,242
| +99% | +$443K | 0.06% | 284 |
|
|
2025
Q1 | $498K | Sell |
4,271
-291
| -6% | -$33.9K | 0.03% | 427 |
|
|
2024
Q4 | $386K | Buy |
4,562
+148
| +3% | +$12.5K | 0.02% | 506 |
|
|
2024
Q3 | $397K | Sell |
4,414
-561
| -11% | -$50.4K | 0.02% | 514 |
|
|
2024
Q2 | $400K | Buy |
4,975
+301
| +6% | +$24.2K | 0.02% | 506 |
|
|
2024
Q1 | $373K | Sell |
4,674
-290
| -6% | -$23.1K | 0.02% | 515 |
|
|
2023
Q4 | $395K | Sell |
4,964
-138
| -3% | -$11K | 0.03% | 461 |
|
|
2023
Q3 | $357K | Buy |
5,102
+67
| +1% | +$4.68K | 0.03% | 449 |
|
|
2023
Q2 | $362K | Sell |
5,035
-16
| -0.3% | -$1.15K | 0.03% | 463 |
|
|
2023
Q1 | $312K | Buy |
5,051
+59
| +1% | +$3.64K | 0.03% | 480 |
|
|
2022
Q4 | $385K | Buy |
4,992
+498
| +11% | +$38.4K | 0.04% | 386 |
|
|
2022
Q3 | $201K | Buy |
+4,494
| New | +$201K | 0.02% | 550 |
|
|
2021
Q4 | – | Sell |
-7,874
| Closed | -$260K | – | 627 |
|
|
2021
Q3 | $260K | Buy |
7,874
+3,077
| +64% | +$102K | 0.02% | 541 |
|
|
2021
Q2 | $324K | Buy |
4,797
+322
| +7% | +$21.7K | 0.02% | 481 |
|
|
2021
Q1 | $253K | Buy |
+4,475
| New | +$253K | 0.02% | 530 |
|